AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02090959
Drug: Ataluren
RxNorm normalized name: Ataluren
DrugBank: Ataluren (DB05016)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Ataluren will be administered per the dose and schedule specified in the arm.
Trial: NCT02580682
Drug: Sanfu herbal patch and moxibustion
RxNorm normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
DrugBank: Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen (DB16709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use Sanfu moxibustion followed by Sanfu herbal patch
Trial: NCT03623711
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: participants take escitalopram tablets based on their severity of depression (10-20mg/day) at least for 12 weeks.
Trial: NCT03899987
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03899987
Drug: Rintatolimod
RxNorm normalized name: Rintatolimod
DrugBank: Rintatolimod (DB16425)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03623711
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: participants take Duloxetine capsule based on their severity of depression (60mg/day) at least for 12 weeks.
Trial: NCT03623711
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: participants take Bupropion tablets based on their severity of depression (75-300mg/day) at least for 12 weeks.
Trial: NCT04502667
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000U or 2000U every 24 hours orally
Trial: NCT01746173
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01746173
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01746173
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01746173
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01746173
Drug: Plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01746173
Drug: Palifermin
RxNorm normalized name: palifermin
DrugBank: Palifermin (DB00039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01746173
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01746173
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01746173
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04552808
Drug: Yimitasvir Phosphate
RxNorm normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort A: On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects
Trial: NCT01689337
Drug: Sprifermin (AS902330)
RxNorm normalized name: Sprifermin
DrugBank: Sprifermin (DB12616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sprifermin (AS902330) will be administered at a dose of 30 microgram (mcg) as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
Trial: NCT01689337
Drug: Sprifermin (AS902330)
RxNorm normalized name: Sprifermin
DrugBank: Sprifermin (DB12616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
Trial: NCT02431013
Drug: Cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol 100 mg twice a day for 6 days \& on Day 8 with statin.
Trial: NCT04552808
Drug: Yimitasvir Phosphate
RxNorm normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort B: were subjects with moderate liver function impairment. On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
Trial: NCT00997334
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00560963
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03913234
Drug: Ribociclib, Trastuzumab, Letrozole
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase IB: letrozole 2.5mg (fixed dose), trastuzumab (8mg/kg loading followed by 6mg/kg q 3weeks, fixed dose) plus ribociclib (dose escalation from 200mg to 600mg) to identify recommended phase iI dose (RPIID) Phase II: letrozole, trastuzumab (same as phase IB) plus ribocicilb RPIID
Trial: NCT01182025
Drug: Xiyanping Injection with western medicine
RxNorm normalized name: western ragweed pollen extract Injectable Suspension
DrugBank: Ragweed pollen extract (DB05368)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Symptomatic treatment using the same treatment methods in western therapy group;~2. Symptomatic treatment using the same treatment methods in Xiyanpin injection group.
Trial: NCT00641056
Drug: Exenatide Once Weekly
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, 2.0mcg, once weekly
Trial: NCT00641056
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: subcutaneous injection, variable dose, QD
Trial: NCT01923558
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil Hydrochloride tablets,23 mg
Trial: NCT01627132
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100mg QD
Trial: NCT00822172
Drug: cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Background therapy beginning at 50mg (1 pill) taken by mouth two times per day for two to three weeks. Then 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for one to two weeks.~Randomized therapy will consist of 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for approximately 180 days.
Trial: NCT02584582
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02584582
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02818816
Drug: brimonidine tartrate 0.2%
RxNorm normalized name: BRIMONIDINE TARTRATE 0.2% SOLN,OPH
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alpha adrenergic receptor agonist
Trial: NCT01703351
Drug: 0.5% ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (n=48); continuous paravertebral infusion of local anesthetics (0.5% ropivacaine, 5cc/hr for 60 hours after operation) thorough catheter below the parietal pleura using On-Q® system(I-flow corp, Lake Forest, CA, USA)
Trial: NCT03485625
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
Trial: NCT03485625
Drug: paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
Trial: NCT01276977
Drug: Zolmitriptan 5 mg Nasal Spray
RxNorm normalized name: ZOLMITRIPTAN 5 mg NASAL SPRAY
DrugBank: Zolmitriptan (DB00315)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will treat 2 migraine attacks with zolmitriptan 5 mg nasal spray and 2 migraine attacks with eletriptan.
Trial: NCT01276977
Drug: Eletriptan 40 mg tablet
RxNorm normalized name: eletriptan
DrugBank: Eletriptan (DB00216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will treat 2 migraine attacks with Eletriptan and 2 migraine attacks with zolmitriptan 5 mg nasal spray
Trial: NCT02064036
Drug: Casodex
RxNorm normalized name: Casodex
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
Trial: NCT02972866
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
Trial: NCT05337969
Drug: Metformin and Vildagliptin 850/50 mg
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg Vildagliptin + 850 mg Metformin as single-dose per study period
Trial: NCT00738582
Drug: MORAb-009 (Amatuximab)
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MORAb-009 (Amatuximab) by IV on Days 1 and 8 every 21 days for 6 cycles.
Trial: NCT00738582
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed 500 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
Trial: NCT00738582
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
Trial: NCT00185484
Drug: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)
RxNorm normalized name: drospirenone
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral administration of YAZ (0.02mg ethinyl estradiol-ß-cyclodextrin clathrate and 3mg drospirenone, 24 day hormone tablets followed by 4 days of placebo tablets for 13 cycles
Trial: NCT04171726
Drug: Edoxaban
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A non-vitamin K antagonist (VKA) oral anticoagulant that selectively inhibits factor Xa.
Trial: NCT02064036
Drug: Leuprolide
RxNorm normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
Trial: NCT02121197
Drug: Ozurdex
RxNorm normalized name: Ozurdex
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04722562
Drug: Vericiguat (BAY1021189)
RxNorm normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)
Trial: NCT04520360
Drug: Carisbamate
RxNorm normalized name: carisbamate
DrugBank: Carisbamate (DB12338)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carisbamate is currently under investigation as an adjuvant antiepileptic therapy in Lennox-Gastaut patients. Lennox-Gastaut syndrome (LGS) is a rare and highly debilitating form of childhood epilepsy that typically is diagnosed between 2 and 8 years of age, with peak onset at 3 to 5 years of age, and frequently persists into adulthood. Treatment options are limited and complicated by the multiple seizure types associated with LGS. Given the breadth of physical and cognitive disabilities associated with LGS, the development of antiseizure medications with appropriate oral dosing forms is needed to ensure administration feasibility and compliance in the target population.
Trial: NCT01122251
Drug: Lercanidipine + Valsartan
RxNorm normalized name: valsartan and lercanidipine
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: L10/V80, L20/V80, L10/V160, L20/V160
Trial: NCT04552808
Drug: Yimitasvir Phosphate
RxNorm normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort C: Cohort C are healthy subjects, cohorts C and D, should be matched in terms of sex, age, and body mass index (BMI). On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
Trial: NCT04552808
Drug: Yimitasvir Phosphate
RxNorm normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort D: were subjects with severe liver function impairment. On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
Trial: NCT01122251
Drug: Lercanidipine or Valsartan
RxNorm normalized name: valsartan and lercanidipine
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: L10, L20, V80, V160
Trial: NCT00005652
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01264822
Drug: Rabeprazole Sodium
RxNorm normalized name: Rabeprazole Sodium
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The following 3 drugs are taken orally at the same time twice daily for 7 days: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and clarithromycin 200 mg.~The dose of clarithromycin may be properly increased as needed, although the upper limit is 400 mg twice daily.~If Helicobacter pylori eradication with proton pump inhibitor, amoxicillin, and clarithromycin fails, the following 3 drugs will be taken at the same time twice daily for 7 days as an alternative treatment for adults: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and metronidazole 250 mg.
Trial: NCT03542461
Drug: Nivolumab 10 MG/ML Intravenous Solution
RxNorm normalized name: nivolumab 10 mg/mL intravenous solution
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 240 mg as a 30 minutes IV infusion on Day 1 of each treatment cycle every 2 weeks, until intolerable toxicity or patient refusal or investigator's decision. In case of disease progression the treatment should be discontinued unless documented clinical benefits in the Investigator's judgement (no rapid progression, tolerance of trial drug, stable performance status, treatment maintenance does not delay an imminent intervention to prevent serious complication of PD) and no evidence of further progression at a radiographic assessment performed within 6 weeks. No dose escalations or reduction allowed. Administration delay until 6 weeks as well as resuming dose are allowed according to protocol defined criteria.
Trial: NCT00559702
Drug: natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: natalizumab
Trial: NCT01153919
Drug: ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT01764386
Drug: NB
RxNorm normalized name: Nb
DrugBank: Niobium (DB13031)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone SR 32 mg/Bupropion SR 360 mg (NB) in combination tablets (daily dosage)
Trial: NCT02170792
Drug: BIBR 1048 MS
RxNorm normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low, medium or high dose
Trial: NCT02170792
Drug: Ranitidine
RxNorm normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg
Trial: NCT03280667
Drug: Pembrolizumab plus denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pembrolizumab 200 mg IV every 3 weeks plus denosumab 120 mg SC on day 1, 8, 22 and then every 3 weeks with daily oral calcium and vitamin D
Trial: NCT00495287
Drug: cytosine arabinoside
RxNorm normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm A: use of standard-dose cytosine arabinoside (100 mg/m2/bd iv. on days 1-7) in association with idarubicin and etoposide.~Arm B: use of high-dose cytosine arabinoside (1000-2000 mg/m2/bd according to age +/-65 years iv. on days 1-2 and 8-9) in association with idarubicin.
Trial: NCT00824161
Drug: TAS-109
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day continuous central intravenous infusion at a dose of 2.0 mg/m2/day followed by a 7-day rest period.~Number of cycles: until unacceptable toxicity or disease progression requires discontinuation.
Trial: NCT00666679
Drug: Comparator: mometasone
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mometasone (inhalation powder, 220 mcg once-daily, for approximately 6 weeks)
Trial: NCT00666679
Drug: Comparator: montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: montelukast (inhalation powder, 1 mg once-daily, for approximately 2 weeks)
Trial: NCT00893984
Drug: Nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control.
Trial: NCT02344563
Drug: Meropem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00536783
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01607658
Drug: Medium dose TBS-2
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
Trial: NCT02748512
Drug: FAI Insert administered using the Mk II inserter
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01607658
Drug: High dose TBS-2
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
Trial: NCT04066543
Drug: Anlotinib Hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib hydrochloride capsule, according to the recommended dose, po, qd, continuous oral 2 weeks stop for 1 week, 3 weeks for a cycle.
Trial: NCT04525300
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Randomization was performed with the use of a computer-generated system provided by the sponsor. Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification
Trial: NCT03060473
Drug: Ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin 2 gm IV every 6 hours for 2 days
Trial: NCT03060473
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 500 mg PO every 8 hours for 5 days (Azithromycin ARM) Amoxicillin 250 mg PO every 8 hours for 5 days (Erythromycin ARM)
Trial: NCT02786979
Drug: Beraprost
RxNorm normalized name: beraprost
DrugBank: Beraprost (DB05229)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02786979
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00376480
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00376480
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00376480
Drug: thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00268411
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00268411
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03623646
Drug: Chemoradiotherapy arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation Therapy in combination with Chemotherapy (Cisplatin)
Trial: NCT03623646
Drug: Immunotherapy + Radiotherapy arm
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation Therapy in combination with Immunotherapy drug (Durvalumab)